Picton Mahoney Asset Management’s Ibere Pharmaceuticals IBER Stock Holding History

Picton Mahoney Asset Management’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$2.02M	–	712
2022 Q4	$2.02M	Hold	200,000	–	–	0.1%	289
2022 Q3	$1.98M	Hold	200,000	–	–	0.07%	323
2022 Q2	$1.96M	Hold	200,000	–	–	0.07%	408
2022 Q1	$1.96M	Hold	200,000	–	–	0.07%	400
2021 Q4	$1.94M	Hold	200,000	–	–	0.05%	439
2021 Q3	$1.94M	Hold	200,000	–	–	0.07%	392
2021 Q2	$1.93M	Buy	+200,000	New	+$1.95M	0.06%	388

Picton Mahoney Asset Management's IBER Position: Q1 2023 in Review

Picton Mahoney Asset Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 200,000 shares — an estimated $2.02M sold.

Picton Mahoney Asset Management first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $2.02M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Picton Mahoney Asset Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Picton Mahoney Asset Management sold 200,000 Ibere Pharmaceuticals shares in Q1 2023, an estimated $2.02M.
Picton Mahoney Asset Management first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Picton Mahoney Asset Management's Ibere Pharmaceuticals position peaked at $2.02M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2023, filed 8 May 2023.